- A meta-analysis of 7 trials (545 patients) found Boswellia serrata extract meaningfully reduced osteoarthritis pain and stiffness versus placebo[1]
- A double-blind placebo-controlled trial of 111 patients found PEA significantly reduced knee osteoarthritis symptoms at both 300 mg and 600 mg daily doses[2]
- No published trial has tested PEA and Boswellia head-to-head; comparisons have to be made across separate studies, not a single controlled matchup
- The two compounds work through different anti-inflammatory pathways (COX-2/5-LOX inhibition for Boswellia, mast cell modulation for PEA), which is why some formulations combine rather than choose between them
Boswellia serrata (Indian frankincense) and PEA are two of the most commonly recommended natural anti-inflammatory options for joint pain, and they get compared often in supplement forums and buying guides. What’s missing from most of those comparisons is that no researcher has actually run a head-to-head trial putting the two directly against each other. What exists instead is separate research on each compound, tested against placebo or standard drugs in similar osteoarthritis populations, which still allows for a reasonably grounded comparison, just not a definitive one.
The Boswellia Evidence
Boswellia’s research base for joint pain is larger and older than PEA’s. A 2020 systematic review and meta-analysis pooled 7 randomized controlled trials covering 545 osteoarthritis patients and found Boswellia and its extracts produced meaningful reductions in pain (measured by VAS and WOMAC pain scores), stiffness, and improved joint function compared to control groups. The review noted benefits typically became apparent after at least 4 weeks of continuous use at doses of 100 to 250 mg[1]. Mechanistically, Boswellia works primarily by inhibiting 5-lipoxygenase (5-LOX) and COX-2, two enzymes involved in producing the inflammatory mediators (leukotrienes and prostaglandins) that drive joint pain and swelling.
The PEA Evidence
PEA’s human osteoarthritis evidence is smaller but more recent. A double-blind, placebo-controlled trial in Brisbane enrolled 111 adults with mild to moderate knee osteoarthritis and randomized them to 300 mg PEA, 600 mg PEA, or placebo daily for 8 weeks. Both PEA doses produced a statistically significant reduction in total WOMAC score compared to placebo (300 mg: p = 0.0372; 600 mg: p = 0.0012), with the higher dose showing the stronger effect[2]. Separately, an animal study using the standard monosodium iodoacetate-induced osteoarthritis model found PEA reduced knee joint swelling and cartilage degradation without adverse effects on body weight, liver, or kidney markers[3]. Some independent evidence reviewers have noted that while the human trial’s results were statistically significant, the trial alone isn’t yet considered strong enough evidence to recommend PEA as routine, first-line osteoarthritis therapy, an honest caveat worth keeping in mind rather than treating either compound’s evidence as settled.
Comparing the Two Fairly
Since there’s no direct trial, any comparison has to account for differences in study design, dose, and duration rather than treating the two bodies of evidence as perfectly parallel. Boswellia’s meta-analysis pools multiple smaller trials at lower doses (100 to 250 mg) over a similar or shorter timeframe; PEA’s key trial is a single, larger, well-controlled study at higher doses (300 to 600 mg). Both showed statistically significant improvement over placebo or control in their respective research. Neither compound has been shown to outperform the other because that comparison has never actually been tested.
Why Some Products Combine Them
Because Boswellia and PEA act through different anti-inflammatory pathways, cartilage-protective enzyme inhibition for Boswellia, local mast-cell modulation for PEA, researchers have started exploring combination formulations rather than treating the two as competitors. One published formulation approach pairs PEA with Boswellia, Cissus quadrangularis, and propolis specifically because the mechanisms are considered complementary rather than redundant. This is still an early, exploratory line of research rather than an established combination therapy with its own large trial base, but it reflects how researchers in this space are thinking about the two compounds: as different tools for the same underlying inflammatory process, not as substitutes for each other.
Practical Considerations
Boswellia has the longer track record and a broader trial base specifically in osteoarthritis; PEA has a smaller but more recent and well-controlled human trial plus a wider research base across other pain conditions (neuropathic pain, fibromyalgia, chronic pelvic pain) that Boswellia’s research doesn’t cover in the same depth. Neither has serious safety concerns reported in the trials described here, though Boswellia can occasionally cause gastrointestinal upset and PEA’s most common complaint is also mild GI discomfort. Anyone managing joint inflammation alongside other chronic pain conditions might find PEA’s broader evidence base more relevant to their overall situation; someone focused specifically on osteoarthritis with a longer track record in mind might lean toward Boswellia’s larger, pooled trial data.
FAQ
Has anyone directly compared PEA and Boswellia in the same trial?
No. Every comparison, including this one, is built from separate studies against placebo or control groups, not a single head-to-head trial.
Which has stronger evidence for osteoarthritis, PEA or Boswellia?
Boswellia has a larger pooled evidence base (7 trials, 545 patients). PEA’s key human trial is a single, well-controlled study of 111 patients, smaller in scale but methodologically solid[1][2].
Can PEA and Boswellia be taken together?
Early research explores combining them because they work through different anti-inflammatory pathways, though there’s no large trial specifically testing the combination for safety or added benefit.
Is either PEA or Boswellia a replacement for standard osteoarthritis care?
No. Both are supported by real trial data as adjunct anti-inflammatory options, not as replacements for a clinician-guided osteoarthritis treatment plan.
References
- Yu G, Xiang W, Zhang T, Zeng L, Yang K, Li J. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020;20(1):225. PMID 32680575
- Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019;27(3):475-485. Inflammopharmacology 2019
- Jung JI, Lee HS, Jeon YE, Kim SM, Hong SH, Moon JM, Lim CY, Kim YH, Kim EJ. Anti-inflammatory activity of palmitoylethanolamide ameliorates osteoarthritis induced by monosodium iodoacetate in Sprague-Dawley rats. Inflammopharmacology. 2021;29(5):1475-1486. PMID 34468900
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
